A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+)
The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.
Abstract
In August 2003, the 284-bed community hospital Pierre-Le Gardeur (PLGH) in Quebec experienced a major outbreak associated with the Clostridium difficile NAP1/027/BI strain. Augmented standard preventive measures (SPMs) were not able to control this outbreak. It was decided in February 2004 to give to every adult inpatient on antibiotics, without any exclusion, a probiotic (Bio-K+: Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2) within 12 hours of the antibiotic prescription. Augmented SPMs were continued. The use of the probiotic in addition to SPMs was associated with a marked reduction of C. difficile infection (CDI). During the 10 years of observation, 44 835 inpatients received Bio-K+, and the CDI rate at PLGH declined from 18.0 cases per 10,000 patient-days and remained at low mean levels of 2.3 cases per 10,000 patient-days. Additionally, 10-year data collected by the Ministry of Health in Quebec comparing the CDI rate between Quebec hospitals showed that CDI rates at PLGH were consistently and continuously lower compared with those at similar hospitals. Blood cultures were monitored at PLGH for Lactobacillus bacteremia through the 10 years' experience, and no Lactobacillus bacteremias were detected. Despite the limitation of an observational study, we concluded that the probiotic Bio-K+ was safe and effective in decreasing our primary CDI rate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“No cases of LB were found in 44,850 adult patients over a 10-year period (2005–2014) surveillance period [65]”
From Lactobacillus Bacteremia and Probiotics: A Review (2023) · cites this paper as [65]
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“plant treatment in accordance with a recently published article [15].”
ResultWarny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E., & McDonald, L. C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67420-x · Cited by 1,430
McFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872
Newberry, S. J. (2012) · JAMA · doi:10.1001/jama.2012.3507 · Cited by 870
Johnston, B. C., Ma, S. S. Y., Goldenberg, J. Z., Thorlund, K., Vandvik, P. O., Loeb, M., & Guyatt, G. H. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-12-201212180-00563 · Cited by 367
Gao, X. W., Mubasher, M., Fang, C. Y., Reifer, C., & Miller, L. E. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.11 · Cited by 318 · cited 2×
“itous, given recently published data from randomized controlled trials using this same formulation [4, 12, 13].”
MethodBeausoleil, M., Fortier, N., Guénette, S., L’Ecuyer, A., Savoie, M., Franco, M., Lachaîne, J., & Weiss, K. (2007) · Canadian Journal of Gastroenterology · doi:10.1155/2007/720205 · Cited by 162 · cited 1×
“itous, given recently published data from randomized controlled trials using this same formulation [4, 12, 13].”
Is primary prevention of Clostridium difficile infection possible with specific probiotics?
Johnson, S., Maziade, P.-J., McFarland, L. V., Trick, W., Donskey, C., Currie, B., Low, D. E., & Goldstein, E. J. C. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.06.005 · Cited by 117
Self-citationDylewski, J., Psaradellis, E., & Sampalis, J. (2010) · Archives of Medical Science · doi:10.5114/aoms.2010.13508 · Cited by 72
Effectiveness of Hand Hygiene for Removal of Clostridium difficile Spores from Hands
Edmonds, S. L., Zapka, C. A., Kasper, D., Gerber, R. A., McCormack, R. R., Macinga, D. R., Johnson, S., Sambol, S. P., Fricker, C. M., Arbogast, J. W., et al. (2013) · Infection Control and Hospital Epidemiology · doi:10.1086/669521 · Cited by 61
Cited by
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide
Sniffen, J. C., McFarland, L. V., Evans, C. T., & Goldstein, E. J. C. (2018) · PLOS ONE · doi:10.1371/journal.pone.0209205 · Cited by 265
Self-citationProbiotics for prevention of Clostridium difficile infection
Mills, J. P., Rao, K., & Young, V. B. (2018) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000410 · Cited by 161
Lactobacillus Bacteremia and Probiotics: A Review
Kullar, R., Goldstein, E. J. C., Johnson, S., & McFarland, L. V. (2023) · Microorganisms · doi:10.3390/microorganisms11040896 · Cited by 156
“rhamnosus CLR2, BioK+®) were followed for any complications of probiotic use [65,66].”
BackgroundSelf-citationClostridium difficile – From Colonization to Infection
Schäffler, H., & Breitrück, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00646 · Cited by 174
“3 cases per 10,000 patients-days during the 10-year observation period (Maziade et al., 2015).”
BackgroundResultInfluentialAdvances in the diagnosis and treatment of Clostridium difficile infections
Peng, Z., Ling, L., Stratton, C. W., Li, C., Polage, C. R., Wu, B., & Tang, Y. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-017-0019-4 · Cited by 103
Probiotics and the prevention of necrotizing enterocolitis
Underwood, M. A. (2018) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2018.08.055 · Cited by 106
Spinler, J. K., Auchtung, J. M., Brown, A., Boonma, P., Oezguen, N., Ross, C. L., Luna, R. A., Runge, J. K., Versalovic, J. A., Peniche, A. G., et al. (2017) · Infection and Immunity · doi:10.1128/iai.00303-17 · Cited by 92
Louh, I. K., Greendyke, W. G., Hermann, E. A., Davidson, K. W., Falzon, L., Vawdrey, D. K., Shaffer, J. A., Calfee, D. P., Furuya, E. Y., & Ting, H. H. (2017) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2016.324 · Cited by 82
“5 of 10,000 patient days in similar hospitals in the region.(24,25) In contrast, an observational study reported no difference in CDI (9.”
The development of probiotics for women’s health
Reid, G. (2017) · Canadian Journal of Microbiology · doi:10.1139/cjm-2016-0733 · Cited by 66
“…weight premature babies (Sawh et al. 2016) (including in London, ON after 10 years of advocating), and to prevent antibiotic associated diarrhea including Clostridium difficile infections (Hickson et al. 2007; Maziade et al. 2015), albeit not all studies have shown efficacy (Allen et al. 2013).”
BackgroundMcFarland, L. V., Ship, N., Auclair, J., & Millette, M. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.04.017 · Cited by 62
Dieterle, M. G., Rao, K. K., & Young, V. B. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13958 · Cited by 71
Alberda, C., Marcushamer, S., Hewer, T., Journault, N., & Kutsogiannis, D. J. (2018) · Nutrients · doi:10.3390/nu10050539 · Cited by 63
“3 cases per 10,000 patient-days when a mixture of Lactobacilli was implemented along with standard protective measures [17].”
BackgroundImpact of probiotics on necrotizing enterocolitis
Underwood, M. A. (2017) · Seminars in Perinatology · doi:10.1053/j.semperi.2016.09.017 · Cited by 54
“(a total of 44,835 inpatients over a decade) resulted in a dramatic decrease in Clostridium difficile infection with no cases of Lactobacillus bacteremia.(91) Infections with L.”
BackgroundGut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults
Vasilescu, I.-M., Chifiriuc, M. C., Pîrcălăbioru, G. G., Filip, R., Bolocan, A., Lazăr, V., Diţu, L.-M., & Bleoţu, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.651081 · Cited by 61
Wu, Z., Xu, Q., Gu, S., Chen, Y., Lv, L., Zheng, B., Wang, Q., Wang, K., Wang, S., Xia, J., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.841920 · Cited by 57
Probiotics for Prevention and Treatment of Clostridium difficile Infection
Valdés-Varela, L., Gueimonde, M., & Ruas‐Madiedo, P. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72799-8_10 · Cited by 59
Li, L., Li, M., Chen, Y., Yu, Z., Chen, P., Yu, Z., Cheng, W., Zhang, W., Wang, Z., Gao, X., et al. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1354447 · Cited by 49
Probiotics and prevention of Clostridium difficile infection
Goldstein, E. J. C., Johnson, S., Maziade, P.-J., Evans, C. T., Sniffen, J. C., Millette, M., & McFarland, L. V. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.12.007 · Cited by 45
Self-citationSpinler, J. K., Ross, C. L., & Savidge, T. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.05.007 · Cited by 46
Acid-Suppressive Therapy and Risk of Infections: Pros and Cons
Fisher, L., & Fisher, A. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0519-y · Cited by 43
Chelliah, R., Choi, J.-G., Hwang, S.-B., Park, B., Daliri, E. B., Kim, S., Wei, S., Ramakrishnan, S., & Oh, D. (2018) · Virulence · doi:10.1080/21505594.2018.1518088 · Cited by 39
“beneficial to worms [70] indicates NO Promotes heat – tolerance (stress tolerance) in C.”
BackgroundAdvances in the Microbiome: Applications to Clostridium difficile Infection
Culligan, E. P., & Sleator, R. D. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5090083 · Cited by 39
“3 cases per 10,000 patient-days, in which time the incidence of CDI remained low [85].”
BackgroundMallina, R. K., Craik, J., Briffa, N., Ahluwalia, V., Clarke, J., & Cobb, A. G. (2017) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2017.04.001 · Cited by 34
A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis
Shelby, R. D., Janzow, G. E., Mashburn‐Warren, L., Galley, J. D., Tengberg, N., Navarro, J. B., Conces, M. R., Bailey, M. T., Goodman, S. D., & Besner, G. E. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1814119 · Cited by 30
“difficile colitis.(3,11,21) Probiotics are theoretically efficacious because of their potential to restore eubiosis to the gastrointestinal microbiota after disruption by antimicrobials.”
BackgroundBainum, T. B., Reveles, K. R., Hall, R. G., Cornell, K., & Álvarez, C. A. (2023) · Microorganisms · doi:10.3390/microorganisms11020387 · Cited by 33
“A publication by Maziade and colleagues described 10 years worth of data on over 44,000 inpatients given a probiotic containing Lactobacillus acidophilus, Lacticaseibacillus casei, and Lacticaseibacillus rhamnosus prophylactically within 12 h of each antibiotic course [15].”
BackgroundZhang, Y., Fleur, A. S., & Feng, H. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2052698 · Cited by 30
Leal, J. R., Heitman, S. J., Conly, J. M., Henderson, E. A., & Manns, B. (2016) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2016.134 · Cited by 27
Probiotics from the standpoint of evidence-based medicine
Кайбышева, В. О., & Nikonov, E. L. (2019) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro2019803145 · Cited by 32
Aroutcheva, A., Auclair, J., Frappier, M., Millette, M., Lolans, K., de Montigny, D., Carrière, S., Sokalski, S., Trick, W. E., & Weinstein, R. A. (2016) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-016-9209-y · Cited by 25
Therapies on the horizon forClostridium difficileinfections
McFarland, L. V. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1161025 · Cited by 29
“[25] Probiotic coverage for inpatients given antibiotics may be a promising approach to prevent CDI in healthcare facilities.”
BackgroundGarza‐González, E., Mendoza-Olazarán, S., Morfín‐Otero, R., Ramírez-Fontes, A., Rodríguez‐Zulueta, P., Flores-Treviño, S., Bocanegra‐Ibarias, P., Maldonado-Garza, H. J., & Camacho-Ortíz, A. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/4549298 · Cited by 23
“This effect is mainly attributable to their acidophilic effect and lowering of pH in the intestinal microenvironment [7, 8].”
BackgroundRecent advances in the treatment of C. difficile using biotherapeutic agents
Giau, V. V., Lee, H., An, S. S. A., & Hulme, J. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s207572 · Cited by 25
“Recently, a decadelong study examining the efficacy of a three-strain probiotic mixture involving 45,000 patients was reported.(56) The probiotic mixture BioK+® (containing Lactobacillus acidophilus CL1285, Lactobacillus rhamnosus CLR2 and Lactobacillus casei LBC80R) was administered 2–12 hrs after antibiotic treatmen…”
BackgroundMaia, A. R., Reyes-Ramírez, R., Pizarro‐Guajardo, M., Saggese, A., Castro-Córdova, P., Isticato, R., Ricca, E., Paredes‐Sabja, D., & Baccigalupi, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041277 · Cited by 18
“difficile toxins [9,10] have not been successful so far, while fecal microbiota transplantation [11,12] and probiotic therapies [13], although very promising, are still under investigation.”
BackgroundLi, T., Lyu, L., Zhang, Y., Dong, K., Li, Q., Guo, X., & Zhu, Y. (2020) · Genomics · doi:10.1016/j.ygeno.2020.09.032 · Cited by 17
Chiu, C.-W., Tsai, P.-J., Lee, C., Ko, W., & Hung, Y. (2021) · Pathogens · doi:10.3390/pathogens10060649 · Cited by 23
“3 cases per 10,000 patient days among adult inpatients treated with antibiotics [48].”
BackgroundMaziade, P.-J., Ship, N., Sniffen, J. C., & Goldstein, E. J. C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab414 · Cited by 15
“Eligible adults took 1 capsule (adults aged ≤49 years) or 2 capsules (adult aged ≥50 years) daily of a probiotic including Lactobacillus acidophilus CL1285, Lacticaseibacillus (Lactobacillus) casei LBC80R, and Lacticaseibacillus (Lactobacillus) rhamnosus CLR2 (Bio-K+ 50 Billion [50 billion colony-forming units per cap…”
Self-citationModulation of the gut microbiota: opportunities and regulatory aspects
Ribaldone, D. G., Pellicano, R., Fagoonee, S., & Actis, G. C. (2022) · Minerva Gastroenterology · doi:10.23736/s2724-5985.22.03152-7 · Cited by 15
Horvat, S., Mahnič, A., Breskvar, M., Džeroski, S., & Rupnik, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15434-1 · Cited by 16
McFarland, L. V., Johnson, S., & Evans, C. T. (2020) · American Journal of Infection Control · doi:10.1016/j.ajic.2020.08.003 · Cited by 13
Primary prevention of Clostridium difficile infections – how difficult can it be?
McFarland, L. V. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1312343 · Cited by 11
Técnicas e Materiais Empregados na Microencapsulação de Probióticos
Vaniski, R., Corti, D., & Drunkler, D. A. (2017) · Brazilian Journal of Food Research · doi:10.3895/rebrapa.v8n1.3651 · Cited by 20
Standard mouse diets lead to differences in severity in infectious and non-infectious colitis
Denny, J. E., Flores, J. N., Mdluli, N. V., & Abt, M. C. (2025) · mBio · doi:10.1128/mbio.03302-24 · Cited by 9
Leal, J. R., Shen, Y., Faris, P., Dalton, B., Sabuda, D. M., Ocampo, W., Bresee, L. C., Chow, B., Fletcher, J. R., Henderson, E., et al. (2023) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2023.169 · Cited by 8
Clostridium difficile Infection: Pathogenesis, Diagnosis and Treatment
Fernández-García, L., Blasco, L., López, M. C., & Tomás, M. (2017) · InTech eBooks · doi:10.5772/67754 · Cited by 12
Probiotics for Prevention and Treatment of Clostridium difficile Infection
Valdés-Varela, L., Gueimonde, M., & Ruas‐Madiedo, P. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-42108-2_6 · Cited by 8
Primary prevention of Clostridioides difficile infection with combination probiotics
Nagamine, T. (2019) · Journal of Hospital Infection · doi:10.1016/j.jhin.2019.10.014 · Cited by 2
Jenest, M. A., Fugit, R. V., Wright, J. L., Bessesen, M. T., & Kon, S. E. (2025) · Antibiotics · doi:10.3390/antibiotics14121225 · Cited by 2
“Two prospective observational studies of BioK+ performed in a large Canadian hospital system showed large reductions in C. difficile incidence associated with introduction of prophylaxis with BioK+ [12,13].”
Clostridium Difficile Infections: Epidemiology, Diagnosis, and Treatment
McFarland, L. V., Surawicz, C. M., & Vindigni, S. M. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch19 · Cited by 1
Etifa, P. (2021) · University of Hertfordshire Research Archive (University of Hertfordshire) · doi:10.18745/th.23919 · Cited by 3
Pearls in Infection Control for Clostridium difficile Infections in Healthcare Facilities
Camacho-Ortíz, A., & Chávez-Moreno, S. (2017) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-017-0114-z
The Use of Probiotics in the Prevention of Clostridium Difficile InfectionPreprint
Mook, L. F. (2016) · doi:10.28971/532016ml85
McFarland, L. V. (2019) · American Journal of Infection Control · doi:10.1016/j.ajic.2019.10.027
Moreau, G. B., Ozbek, H., Kumar, P., Frisbee, A. L., Leslie, J. L., & Petri, W. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.23.453497
Labenz, J. (2019) · Gastro-News · doi:10.1007/s15036-019-0691-4
“Die CDI-Inzidenz wurde durch die konsequente und frühzeitige Gabe des Probiotikums parallel zur Antibiose signi£kant und nachhaltig verringert [23].”
BackgroundDupont, A. W., & Khurana, S. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732648860.793579203
Current insights into microbiome-based therapy. Review
Ткач, С. М., Dorofeyev, A. E., & Lm, R. (2024) · Modern Gastroenterology · doi:10.30978/mg-2024-1-73
Control of Clostridioides difficile by Bacteriocin-Producing Lactococcus lactis CJNU 3001
Lee, H.-J., Hong, Y.-B., Lee, J.-H., & Moon, G. (2024) · Current Topic in Lactic Acid Bacteria and Probiotics · doi:10.35732/ctlabp.2024.10.1.56
Tronnet, A. (2022) · theses.fr (ABES) · doi:10.70675/c8ae498fz2b4dz478fz8da7z895713b7dd36
Strategies for the Prevention of Clostridioides difficile Infections
McFarland, L. V. (2026) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2026.05.002
Probiotics for Primary or Secondary Prevention of Clostridioides difficile Infection
Kaiser-Powers, T., & Weingarden, A. R. (2026) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2026.05.004
Metadata
- Authors
- Maziade, P.-J., Pereira, P., & Goldstein, E. J. C.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Maziade, Pierre-Jean
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-28
- Volume
- 60
- Issue
- suppl_2
- Pages
- S144-S147
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W1970561648
- Cited by
- 60
- References
- 15
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 7 · 2018: 9 · 2017: 10 · 2016: 9
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Keywords
- Clostridium difficile infection, primary prevention, probiotics, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, antibiotic-associated diarrhea, hospital outbreak, community hospitals
- MeSH terms
- Adult, Anti-Bacterial Agents, Clostridium Infections, Diarrhea, Disease Outbreaks, Follow-Up Studies, Hospitals, Community, Humans, Lactobacillus acidophilus, Lacticaseibacillus casei, Primary Prevention, Prospective Studies, Quebec, Time Factors, Cohort Studies, Clostridioides difficile, Bacteremia, Probiotics, Lacticaseibacillus rhamnosus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.